Full-Time
Vice President
Health Economics and Outcomes Research, Regulatory Sciences
Posted on 11/23/2025
ProPharma Group
1,001-5,000 employees
Regulatory sciences consultant for life sciences
No salary listed
Germany + 2 more
More locations: Ireland | United Kingdom
In Person
 Legal & Compliance (5) |
|---|
| , , , , |
- Experience leading and managing a team of health economics and outcomes research (HEOR) and market access professionals.
- Strategic leadership and subject matter expertise in health technology assessment (HTA), pricing and reimbursement, and evidence generation.
- Experience developing HEOR strategies to support successful market access, including joint clinical assessments (Joint Clinical Assessments) (JCA), joint scientific consultations (JSC), and local HTA submissions.
- Ability to guide the development of value dossiers, economic models, real-world evidence plans, and other payer-relevant deliverables.
- Experience leading and delivering flagship HEOR and access projects, ensuring high-quality execution across all phases.
- Experience overseeing project management activities including budget tracking, client communication, invoicing, and service expansion.
- Experience serving as a senior point of contact for clients, providing strategic insights and fostering long-term partnerships.
- Experience representing the company in external engagements with HTA bodies, payers, and industry consortia.
- Experience driving business development initiatives, including proposal development, client presentations, and thought leadership.
- Ability to monitor and interpret evolving HTA and access landscapes across Europe and Rest of World and translate insights into actionable strategies.
- Experience contributing to internal process improvement and innovation within the HEOR function.
- Ability to support the strategic direction of the RS Development team, aligning with business goals such as revenue growth and margin optimization.
- Mentoring, coaching, and line management of senior and junior HEOR staff.
- Lead and manage a team of HEOR and market access experts, ensuring optimal project allocation, utilization, and professional development.
- Provide strategic leadership and subject matter expertise in HTA, pricing and reimbursement, and evidence generation across a diverse portfolio of projects.
- Develop and implement HEOR strategies to support successful market access, including joint clinical assessments (JCA), joint scientific consultations (JSC), and local HTA submissions.
- Guide the development of value dossiers, economic models, real-world evidence plans, and other payer-relevant deliverables.
- Lead and deliver flagship HEOR and access projects, ensuring high-quality execution across all phases.
- Oversee project management activities including budget tracking, client communication, invoicing, and service expansion.
- Serve as a senior point of contact for clients, providing strategic insights and fostering long-term partnerships.
- Represent the company in external engagements with HTA bodies, payers, and industry consortia.
- Drive business development initiatives, including proposal development, client presentations, and thought leadership.
- Monitor and interpret evolving HTA and access landscapes across Europe and RoW and translate insights into actionable strategies.
- Contribute to internal process improvement and innovation within the HEOR function.
- Support the strategic direction of the RS Development team, aligning with business goals such as revenue growth and margin optimization.
- Mentor, coach, and line manage senior and junior HEOR staff.
ProPharma Group provides regulatory sciences consulting and related services for drugs, biologics, medical devices, and diagnostics on a global scale. Its offerings cover the full lifecycle, from early development and clinical trials to regulatory approval and post-market activities. The company’s services include regulatory sciences, clinical research, quality and compliance, pharmacovigilance, medical information, and R&D technology, delivered by a team of over 2,500 professionals with more than 20 years of operation. ProPharma Group differentiates itself by providing expert, end-to-end regulatory and life sciences solutions across multiple product types and stages, helping pharmaceutical, biotechnology, and medical device companies navigate complex regulatory and compliance challenges. The goal is to help clients bring safe and compliant products to market efficiently while maintaining ongoing lifecycle support.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Raleigh, North Carolina
Founded
2001
Simplify's Take
What believers are saying
- Hyderabad office opened November 2025 taps India's $130B pharma growth by 2030.
- Dawn Sherman appointed CEO September 2024 drives global expansion strategy.
- CF Box partnership revolutionizes cell/gene therapy manufacturing support.
What critics are saying
- IQVIA undercuts prices, eroding ProPharma's pharmacovigilance share in 12-24 months.
- Parexel acquisition intensifies clinical research competition in 6-12 months.
- FDA AI tools automate 30% of submissions, reducing consulting demand in 18-36 months.
What makes ProPharma Group unique
- ProPharma delivers end-to-end regulatory sciences across drugs, biologics, and devices.
- Over 2,500 professionals provide pharmacovigilance and clinical research expertise.
- Acquired Clinres Farmacija in 2024 to enhance CRO capabilities in Europe.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 24%ProPharma expands operations with new office in Hyderabad. Modern workspace supports continued growth and innovationRALEIGH, N.C., Dec. 11, 2025 /PRNewswire/ - ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced the official inauguration of its new office in Hyderabad, India, on November 17, 2025. Strategically located in Mindspace, at the heart of Hyderabad's technology corridor (HITEC City/Madhapur), the new office places ProPharma among the world's leading Global Capability Centers (GCCs) in the pharmaceutical industry. Mindspace is also the first commercial business park in Hyderabad to receive a Gold rating from the Indian Green Building Council (IGBC). The prominent placement of the ProPharma logo atop the building underscores the company's growing presence and brand visibility in India.The expansion supports ProPharma's continued growth trajectory by providing capacity for additional team members across multiple service lines and creating a modern, collaborative environment designed to inspire innovation and connection. More than 70 employees participated in the inaugural celebration."This milestone represents an important step forward in ProPharma's global expansion," said Jason DeGoes, President, ProPharma. "Our new Hyderabad office strengthens our ability to deliver high-quality, integrated solutions for our clients around the world and reflects our commitment to building an exceptional environment for our teams.""We're proud to establish a world-class workspace in Hyderabad - one designed to foster creativity, efficiency, and collaboration," added Pavan Hemadri, Director of Business Operations, ProPharma. "This move enhances our ability to attract top local talent and better serve our clients across regulatory, clinical, and compliance domains."The new state-of-the-art facility features open, collaborative workspaces aligned with ProPharma's global culture of innovation and operational excellence. It also underscores ProPharma's long-term investment in India as a key hub supporting its worldwide operations.About ProPharmaFor the last 25 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, FSP solutions, and digital transformation, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate its partners' most high-profile drug and device programs. For more information about ProPharma, please visit propharmagroup.com.About Odyssey Investment PartnersOdyssey Investment Partners is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit odysseyinvestment.com.Logo - https://www.pagalparrot.com/wp-content/uploads/2025/12/ProPharma_Group_Logo.jpg View original content:https://www.prnewswire.co.uk/news-releases/propharma-expands-operations-with-new-office-in-hyderabad-302638474.html
RALEIGH, N.C., Oct. 21, 2024 /PRNewswire/ - ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced that Brian Tuttle has been named Chief Financial Officer.
RALEIGH, N.C., Oct. 9, 2024 /PRNewswire/ - ProPharma, a leading global provider of regulatory, clinical, and compliance services for the life sciences industry, is pleased to announce it has won the prestigious CPHI Pharma Award for Regulatory and Compliance.
RALEIGH, N.C., Sept. 30, 2024 /PRNewswire/ - ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, today announced that Dawn Sherman has been appointed Chief Executive Officer.
ProPharma, a global research consulting company headquartered in the US, has won two awards in the 2024 Clinical Trials Arena Excellence Awards, in the Business Expansion and M&A categories, celebrating its acquisition of the Croatia-based contract research organization (CRO), Clinres Farmacija.